Cargando…
Novel Therapeutic Approaches Targeting Post-Translational Modifications in Lung Cancer
Lung cancer is one of the most common cancers worldwide. It consists of two different subtypes: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Despite novel therapeutic options such as immunotherapy, only 20% of lung cancer patients survive the disease after five years. This l...
Autores principales: | Baietti, Maria Francesca, Sewduth, Raj Nayan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9865455/ https://www.ncbi.nlm.nih.gov/pubmed/36678835 http://dx.doi.org/10.3390/pharmaceutics15010206 |
Ejemplares similares
-
Cracking the Monoubiquitin Code of Genetic Diseases
por: Sewduth, Raj Nayan, et al.
Publicado: (2020) -
Unraveling the Post-Translational Modifications and therapeutical approach in NSCLC pathogenesis
por: Gulhane, Pooja, et al.
Publicado: (2023) -
Editorial: Epigenetic mechanisms and post-translational modifications as novel therapeutic targets in cancer
por: Shi, Zhi, et al.
Publicado: (2022) -
Multi-Omics Integration for the Design of Novel Therapies and the Identification of Novel Biomarkers
por: Ivanisevic, Tonci, et al.
Publicado: (2023) -
Post‐translational modifications of histones: Mechanisms, biological functions, and therapeutic targets
por: Liu, Ruiqi, et al.
Publicado: (2023)